Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.

NCT04916886 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.

NCT NCT04916886
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04916886 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate the Immunogenicity Bridging Between Different Manufacture Scales and Between Different Lots of Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Population 6-59 Years of Age.
Lead sponsor
CanSino Biologics Inc.
Phase
Not applicable
Overall status
Completed
Start date
June 3, 2021
Completion date
July 31, 2022
Enrollment
2,021 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19